Physician profile
Eric J Boyle
NPI 1265682512
$81,594.89
in general payments reported to CMS, 2019-2025
25 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $4,473 · 2021: $4,519 · 2022: $8,790 · 2023: $5,446 · 2024: $17K · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $20K · Food and Beverage: $2,051 · Travel and Lodging: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $20,000.00 |
| Food and Beverage | $2,051.09 |
| Travel and Lodging | $1,133.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $78,796.97 | 2019-2024 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $823.31 | 2019 | |
| Ethicon US, LLC | $738.93 | 2019-2025 | Echelon Circular, Enseal X1, Ethicon |
| Cumberland Pharmaceuticals, INC. | $190.80 | 2019-2025 | Caldolor |
| Novo Nordisk INC | $165.16 | 2023-2025 | Wegovy |
| W. L. Gore & Associates, INC. | $150.56 | 2019-2021 | |
| Smith+Nephew, INC. | $104.54 | 2021-2025 | Renasys Go V2 Home, Collagenase Santyl |
| Stryker Corporation | $98.43 | 2019-2023 | 1688 |
| Davol INC. | $71.67 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $55.24 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $52.94 | 2019 | |
| Endogastric Solutions, INC | $40.90 | 2019 | |
| Innovation Technologies INC | $37.29 | 2021 | |
| Integra Lifesciences Corporation | $37.19 | 2021 | |
| Phathom Pharmaceuticals, INC. | $36.21 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $33.39 | 2023-2025 | Exparel |
| Baxter Healthcare | $26.29 | 2019 | |
| Becton, Dickinson and Company | $24.39 | 2023 | Phasix Mesh |
| Bioventus LLC | $19.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.50 | 2022 | |
| Currax Pharmaceuticals LLC | $16.51 | 2024 | Contrave, Onzetra Xsail |
| Cook Medical LLC | $15.84 | 2019 | |
| Medtronic, INC. | $14.64 | 2024 | Signia |
| Lilly USA, LLC | $13.99 | 2025 | Zepbound |
| Allergan, INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.